UBS Group
SPRB

UBS Group’s Spruce Biosciences SPRB Stock Holding History

UBS Group’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
23,381
+19,462
+497% +$1.09M ﹤0.01% 5523
2026
Q1 		$256K Sell
3,919
-983
-20% -$67.8K ﹤0.01% 6498
2025
Q4 		$427K Buy
4,902
+4,770
+3,614% +$511K ﹤0.01% 6178
2025
Q3 		$1.18K Buy
+132
New +$1.17K ﹤0.01% 9410
2025
Q2 		– Sell
-1,553
Closed -$33.8K – 11153
2025
Q1 		$33.8K Buy
1,553
+406
+35% +$11.3K ﹤0.01% 7862
2024
Q4 		$36.1K Buy
+1,147
New +$42K ﹤0.01% 7501
2024
Q3 		– Sell
-1,759
Closed -$64.4K – 9383
2024
Q2 		$68.3K Buy
1,759
+1,548
+734% +$83K ﹤0.01% 6446
2024
Q1 		$12.4K Buy
211
+205
+3,417% +$52.1K ﹤0.01% 7138
2023
Q4 		$1.42K Buy
+6
New +$693 ﹤0.01% 8310
2023
Q3 		– Hold
0
– – – 9083
2023
Q2 		– Sell
-13
Closed -$2.17K – 8661
2023
Q1 		$2.12K Sell
13
-62
-83% -$11.5K ﹤0.01% 8574
2022
Q4 		$6.21K Sell
75
-25
-25% -$2.09K ﹤0.01% 9066
2022
Q3 		$10K Buy
100
+22
+28% +$3.08K ﹤0.01% 8464
2022
Q2 		$10K Buy
78
+26
+50% +$3.33K ﹤0.01% 8017
2022
Q1 		$8K Sell
52
-19
-27% -$3.54K ﹤0.01% 8715
2021
Q4 		$24K Buy
+71
New +$21.1K ﹤0.01% 7649
2021
Q1 		– Sell
-63
Closed -$115K – 9575
2020
Q4 		$115K Buy
+63
New +$104K ﹤0.01% 5598

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

UBS Group's SPRB Position: Q2 2026 in Review

UBS Group increased its Spruce Biosciences (SPRB) stake by 497% in Q2 2026, buying an estimated $1.09M and bringing the position to 23,381 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #5523.

UBS Group first reported a position in SPRB in Q4 2020 and has held it in 16 quarters since. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • UBS Group held 23,381 shares of Spruce Biosciences worth $1.26M as of Q2 2026.
  • UBS Group bought 19,462 Spruce Biosciences shares in Q2 2026, an estimated $1.09M.
  • Spruce Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5523 holding.
  • UBS Group first reported a position in Spruce Biosciences in Q4 2020 and has held it in 16 quarters since.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.